Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

485A-1

Sigma-Aldrich

ATRX Rabbit Polyclonal Antibody

Sinónimos:

ATP-dependent helicase ATRX, X-linked helicase II, X-linked nuclear protein (XNP)

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

UNSPSC Code:
41116161

biological source

rabbit blood

Quality Level

100
500

conjugate

unconjugated

antibody form

IgG fraction of antiserum

antibody product type

primary antibodies

description

For In Vitro Diagnostic Use in Select Regions

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL (concentrate (485A-14))
vial of 0.1 mL (concentrate (485A-14-RUO) Research Use Only)
vial of 0.5 mL (concentrate (485A-15))
vial of 1.0 mL (concentrate (485A-16))
vial of 1.0 mL (concentrate (485A-16-RUO) Research Use Only)
vial of 1.0 mL (concentrate (485A-17-RUO) Research Use Only)
vial of 1.0 mL (pre-dilute ready-to-use (485A-17))
vial of 7.0 mL (concentrate (485A-18-RUO) Research Use Only)
vial of 7.0 mL (pre-dilute ready-to-use (485A-18))

manufacturer/tradename

Cell Marque

technique(s)

immunocytochemistry: suitable (formalin-fixed, paraffin-embedded sections 1:50-1:50 (concentrated))

isotype

IgG

control

astrocytoma, brain, glioblastoma, oligodendroglioma

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

General description

Diffuse gliomas are classified based on histological and molecular features to achieve an integrated diagnosis. Molecular diagnostic markers include IDH mutation, 1p/19q co-deletion, and TP53 mutation. ATRX is a chromatin remodeling protein and its mutation status may be used as a molecular diagnostic marker within the diff use glioma classification algorithm. Anti-ATRX is used to identify mutant ATRX by a loss of ATRX expression in neoplastic cells when compared with internal positive controls (endothelial cells, glia, and neurons). Grade II/III astrocytoma classification includes IDH mutant, ATRX mutant, and 1p/19q retention, while grade II/III oligodendroglioma includes IDH mutant, ATRX wildtype, and 1p/19q co-deletion; p53 expression may also serve as an aid in diagnosis. ATRX mutation is frequently, but not always, mutually exclusive with 1p/19q co-deletion.

Quality

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Storage Class

12 - Non Combustible Liquids

wgk_germany

WGK 2


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Akane Yamamichi et al.
Brain tumor pathology, 35(2), 106-113 (2018-03-20)
The IDH-mutant and 1p/19q co-deletion (1p19q codel) provides significant diagnostic and prognostic value in lower-grade gliomas. As ATRX mutation and 1p19q codel are mutually exclusive, ATRX immunohistochemistry (IHC) may substitute for 1p19q codel, but this has not been comprehensively examined.
Daniel J Brat et al.
The New England journal of medicine, 372(26), 2481-2498 (2015-06-11)
Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly
Matthew D Wood et al.
Diagnostic pathology, 14(1), 29-29 (2019-04-11)
Insights into the molecular underpinnings of primary central nervous system tumors have radically changed the approach to tumor diagnosis and classification. Diagnostic emphasis has shifted from the morphology of a tumor under the microscope to an integrated approach based on
Masako Ikemura et al.
Histopathology, 69(2), 260-267 (2016-01-08)
We performed an immunohistochemical analysis of alpha-thalassaemia/mental retardation syndrome X-linked (ATRX) expression in adult diffuse gliomas, with reference to clinicopathological and genetic features, to determine the utility of this analysis in diagnostic practice. A total of 193 adult diffuse gliomas
David E Reuss et al.
Acta neuropathologica, 129(1), 133-146 (2014-11-28)
Diffuse gliomas are represented in the 2007 WHO classification as astrocytomas, oligoastrocytomas and oligodendrogliomas of grades II and III and glioblastomas WHO grade IV. Molecular data on these tumors have a major impact on prognosis and therapy of the patients.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico